Structure-based discovery of opioid analgesics with reduced side effects

Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side effects of morphine and related opioids—which include fatal respiratory depression—are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors. Conversely, G-protein μOR signalling is thought to confer analgesia. Here we computationally dock over 3 million molecules against the μOR structure and identify new scaffolds unrelated to known opioids. Structure-based optimization yields PZM21—a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment. Unlike morphine, PZM21 is more efficacious for the affective component of analgesia versus the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.

[1]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[2]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[3]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[4]  Marc G. Caron,et al.  μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence , 2000, Nature.

[5]  Gerald Thiel,et al.  Designer Receptors Exclusively Activated by Designer Drugs , 2015, Neuromethods.

[6]  W. Estes.  Discriminative conditioning; effects of a Pavlovian conditioned stimulus upon a subsequently established operant response. , 1948, Journal of experimental psychology.

[7]  Marc G Caron,et al.  Enhanced Rewarding Properties of Morphine, but not Cocaine, in βarrestin-2 Knock-Out Mice , 2003, The Journal of Neuroscience.

[8]  D Le Bars,et al.  Animal models of nociception. , 2001, Pharmacological reviews.

[9]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[10]  Loren J. Martin,et al.  Olfactory exposure to males, including men, causes stress and related analgesia in rodents , 2014, Nature Methods.

[11]  Jun Ren,et al.  G-protein–gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids , 2016, Anesthesiology.

[12]  H. Morris,et al.  Identification of two related pentapeptides from the brain with potent opiate agonist activity , 1975, Nature.

[13]  Brian K. Shoichet,et al.  Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..

[14]  L. Bohn,et al.  Morphine Side Effects in β-Arrestin 2 Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  Jonathan A Sugam,et al.  Mu Opioid Receptor Modulation of Dopamine Neurons in the Periaqueductal Gray/Dorsal Raphe: A Role in Regulation of Pain , 2016, Neuropsychopharmacology.

[16]  R. A. Moyer,et al.  An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization , 2007, Molecular Pharmacology.

[17]  Kjell Hole,et al.  The formalin test in mice: dissociation between inflammatory and non-inflammatory pain , 1987, Pain.

[18]  Maria F. Sassano,et al.  Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor , 2013, ACS chemical biology.

[19]  A. Basbaum,et al.  The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: Correlation of nociceptive behavior and c-fos expression , 1991, Neuroscience.

[20]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[21]  Bryan L Roth,et al.  Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. , 2010, Assay and drug development technologies.

[22]  R. Bolles.  Species-specific defense reactions and avoidance learning. , 1970 .

[23]  G. Pasternak,et al.  Mu Opioids and Their Receptors: Evolution of a Concept , 2013, Pharmacological Reviews.

[24]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[25]  Guodong Liu,et al.  A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[26]  B. Skinner,et al.  Some quantitative properties of anxiety , 1941 .

[27]  R. Gainetdinov,et al.  Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.

[28]  Vsevolod V. Gurevich,et al.  Design and Analysis of an Arrestin-Biased DREADD , 2015 .

[29]  Graeme Milligan,et al.  G Protein Coupling and Ligand Selectivity of the D2L and D3 Dopamine Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[30]  L. Dykstra,et al.  Thermal sensitivity as a measure of spontaneous morphine withdrawal in mice. , 2013, Journal of pharmacological and toxicological methods.

[31]  S. Humphreys,et al.  Co-Expression of GRK2 Reveals a Novel Conformational State of the µ-Opioid Receptor , 2013, PloS one.

[32]  Clifford J. Woolf,et al.  Long term alterations in the excitability of the flexion reflex produced by peripheral tissue injury in the chronic decerebrate rat , 1984, Pain.

[33]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[34]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[35]  Ralf C. Kling,et al.  Functionally selective dopamine D₂, D₃ receptor partial agonists. , 2014, Journal of medicinal chemistry.

[36]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[37]  Petros Koutrakis,et al.  Chronic Social Stress and Susceptibility to Concentrated Ambient Fine Particles in Rats , 2010, Environmental health perspectives.

[38]  R. Bolles,et al.  Clinical implications of Bolles & Fanselow's pain/fear model , 1980, Behavioral and Brain Sciences.

[39]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[40]  Ralf C. Kling,et al.  Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. , 2013, Journal of medicinal chemistry.

[41]  Jonathan A. Javitch,et al.  Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[42]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[43]  Sung Han,et al.  Elucidating an Affective Pain Circuit that Creates a Threat Memory , 2015, Cell.

[44]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[45]  D C Blanchard,et al.  Passive and active reactions to fear-eliciting stimuli. , 1969, Journal of comparative and physiological psychology.

[46]  P T Brown,et al.  Acute tolerance in morphine analgesia: continuous infusion and single injection in rats. , 1991, Anesthesiology.

[47]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[48]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[49]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[50]  Elliott M. Ross,et al.  Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 Pathway* , 2007, Journal of Biological Chemistry.

[51]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[52]  Maria F. Sassano,et al.  PRESTO-TANGO: an open-source resource for interrogation of the druggable human GPCR-ome , 2015, Nature Structural &Molecular Biology.

[53]  P. Gmeiner,et al.  Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.

[54]  Xin Chen,et al.  Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 , 2015, Nature.

[55]  John Hughes,et al.  Endogenous opioid peptides: multiple agonists and receptors , 1977, Nature.

[56]  Stephen M. Husbands,et al.  Structural insights into μ-opioid receptor activation , 2015, Nature.

[57]  Sudarshan Rajagopal,et al.  Quantifying Ligand Bias at Seven-Transmembrane Receptors , 2011, Molecular Pharmacology.

[58]  R. Rescorla,et al.  INHIBITION OF AVOIDANCE BEHAVIOR. , 1965, Journal of comparative and physiological psychology.

[59]  Sudarshan Rajagopal,et al.  Quantifying biased agonism: understanding the links between affinity and efficacy , 2013, Nature Reviews Drug Discovery.

[60]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[61]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[62]  Michael M. Mysinger,et al.  Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.

[63]  P R Sanberg,et al.  The catalepsy test: its ups and downs. , 1988, Behavioral neuroscience.

[64]  Peter Gmeiner,et al.  Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor. , 2011, Journal of molecular biology.

[65]  B. Skinner,et al.  The Behavior of Organisms: An Experimental Analysis , 2016 .

[66]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[67]  C. Zhang,et al.  Covalent agonists for studying G protein-coupled receptor activation , 2014, Proceedings of the National Academy of Sciences.

[68]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[69]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[70]  Lynn R. Webster,et al.  Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers , 2014, PAIN®.

[71]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[72]  Anton Barty,et al.  Structural basis for bifunctional peptide recognition at human δ-Opioid receptor , 2015, Nature Structural &Molecular Biology.

[73]  Brian K. Shoichet,et al.  Structure-Based Discovery of a Novel, Noncovalent Inhibitor of AmpC β-Lactamase , 2002 .

[74]  Rainer Spanagel,et al.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway , 1992 .

[75]  T. Tzschentke,et al.  Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues , 1998, Progress in Neurobiology.